G

GSK

Develops medicines, vaccines, and consumer health

Pharmaceutical Business and Supply Chain Intern

Summer 2027Updated
£26.4k - £28.9k+ Bonus
Internship
London, UK+4 moreMore locations: Ware, UK | Worthing, UK | Barnard Castle, UK | Montrose, UK
Hybrid
Operations & LogisticsProduction Planning & Scheduling, Supply Chain Management

About the job

Requirements
  • Applicants must have completed at least two years of an undergraduate degree and must not have graduated when the placement begins.
  • Applicants must remain enrolled at a UK or Republic of Ireland university for the duration of the placement.
  • Applicants who have already completed a bachelor’s degree and are currently studying for a postgraduate master’s degree are not eligible.
  • Applicants must be fluent in written and spoken English.
  • Applicants must complete the Connectr activity and obtain a personal application code before applying.
  • Degree requirements vary by role: Role 1 accepts Biomedical Sciences, Engineering, Life Sciences, Supply Chain, or Business backgrounds, but is open to any degree; Role 2 requires Engineering, Supply Chain, or Pharmaceutical Science; Role 3 lists accredited Engineering, Business, Mathematics, Science, Supply Chain, Economics, or Data Analytics; Role 4 lists Engineering, Business, Science, Economics, Supply Chain, Data Analytics, or Digital; Role 5 lists Biomedical, Engineering, or Life Sciences; Role 6 lists Logistics, Manufacturing, or Supply Chain; Role 7 is open to any degree; Role 8 requires Business or Supply Chain.
  • Applicants must successfully complete each recruitment stage to be offered a placement.
Responsibilities
  • Role 1: Engage in warehouse inbound and outbound activities; support departments, global suppliers, contractors, new equipment introduction, and new process implementation; simplify and automate material scheduling; analyze warehouse capacity and report on budget; review demand and market intelligence, forecasts, and supply chain complexity; assess consumables inventory policy; improve data quality.
  • Role 2: Support deployment and embedding of the GSK Production System at the site; help build site personnel capability for day-to-day continuous improvement; support improvement in site performance across quality, safety, service, cost, and innovation; conduct site self-assessments against GPS maturity matrices and help close gaps; coach and train site teams.
  • Role 3: Assist inventory management and incoming-material planning to identify at-risk stock and coordinate actions; support cross-functional batch tracking; participate in scheduling and cross-functional meetings, facilitating issue resolution; develop material-planning standard work; gain exposure to QC Testing, including Chemistry, Microbiology, and Incoming Materials testing; develop digital solutions using AI, Power BI, and Power Apps; support digital improvement and troubleshooting; track Supply & Logistics objectives and KPIs and support projects; drive continuous improvement; apply analytical thinking to business situations.
  • Role 4: Lead and deliver improvement projects; work with suppliers, customers, and colleagues globally; support distribution chains for temperature-sensitive products; build supplier relationships; perform risk management, data analysis, intelligence, and reporting; track performance and third-party supply chain management; develop skills in new-process development and quality systems support.
  • Role 5: Troubleshoot production processes and equipment; support process and technical investigations, corrective and preventative actions, and internal problem notifications; support or own compliance processes including self-inspections, deviation management, safety sampling, local and RMS risk management, laboratory and plant investigations, CAPA, customer and vendor complaints, and planned change; identify process improvements and deliver corrective actions, preventative actions, and minor projects against targets; support inspection readiness and manage audits; maintain production documentation, procedures, and technical records; collaborate with cross-functional teams on operational, quality, and business objectives.
  • Role 6: Schedule production plans for pharmaceutical manufacturing; support business activities through actions, problem solving, and collaboration with support functions; carry out continuous improvement projects; investigate digital solutions for Smart Manufacturing; engage in warehouse inbound and outbound activities.
  • Role 7: Drive continuous improvement across Supply & Logistics; use GSK improvement methodologies to solve priority problems; support warehouse capacity improvement; support Launch & Data and Harmonization teams in improving data delivery; develop and implement digital solutions using Power BI, Power Apps, and other Smart Manufacturing technologies; support improvement projects involving warehouse capacity, material availability, advanced scheduling, and lead-time reduction.
  • Role 8: Deploy GPS standards to support business strategy and performance; develop capability in GPS standards and Lean methodologies; coach and deliver improvement projects; work with the Value Stream Director and Operations Manager on a GPS deployment plan; teach and coach others in GPS standards and data-analysis and problem-solving techniques; introduce GPS standards and standardized ways of working; identify and share best practices across GSK sites.
Desired Qualifications
  • Typical skills to develop include multidisciplinary teamwork, written and verbal communication, time management, problem solving, networking, data analysis and management, and role-specific technical skills.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.